Background/Objective

There are limited real-world studies assessing semaglutide weight loss and associated comorbidity and metabolic outcomes over periods ≥ 6 months. We aim to assess weight loss, metabolic, and cardiovascular outcomes of 12 months of semaglutide.

Subject/Methods

We conducted a multicentered retrospective cohort study on semaglutide use. We included patients with a body-mass index (BMI) ≥ 27 kg/m² who were prescribed weekly semaglutide subcutaneous injections. We excluded patients with bariatric surgeries, taking other anti-obesity medications, and with active malignancy or pregnancy. A total of 1023 patients had semaglutide prescription for obesity.

Intervention/Methods

We assessed weight loss outcomes of subcutaneous semaglutide for 12 months. The primary endpoint was total body weight loss percentage (TBWL%) at 12 months. Secondary endpoints included proportion of patients achieving ≥5%, ≥10%, ≥15%, and ≥20% weight loss, and improvements in metabolic, cardiovascular, and comorbidities after 12 months of follow-up.

Results

We included 304 patients (73% female, 93% White, mean age 48.8 [12.4] years, BMI 40.9 [9.6] kg/m²) in the analysis. Patients achieved a TBWL of 13.4 (8.0)% at 12 months (p < 0.001 from baseline). Patients without T2DM achieved a TBWL of 16.9 (6.9)% compared to 9.9 (8.4)% in patients without T2DM at 12 months on the higher doses of semaglutide (p < 0.001 from baseline). In this cohort, 81% achieved ≥5%, 64% achieved ≥10%, 41% achieved ≥15%, and 22% achieved ≥20% TBWL at 12 months. Patients with overweight or obesity experienced significant improvements in metabolic, lipid profile, blood pressure, liver function tests, and cardiovascular disease risk outcomes.

Conclusions

Semaglutide demonstrated notable improvement in obesity, metabolic, and cardiovascular disease risk outcomes in a clinical setting.

中文翻译：

---

索马鲁肽的减肥和心血管疾病风险结果：一项为期一年的多中心研究

背景/目标

评估索马鲁肽体重减轻以及 ≥ 6 个月期间相关合并症和代谢结果的现实世界研究有限。我们的目标是评估 12 个月索马鲁肽的体重减轻、代谢和心血管结局。

主题/方法

我们对索马鲁肽的使用进行了一项多中心回顾性队列研究。我们纳入了体重指数 (BMI) ≥ 27 kg/m ²的患者，每周接受索马鲁肽皮下注射。我们排除了接受过减肥手术、服用其他抗肥胖药物以及患有活动性恶性肿瘤或怀孕的患者。共有 1023 名患者服用索马鲁肽治疗肥胖症。

干预/方法

我们评估了皮下注射索马鲁肽 12 个月的减肥效果。主要终点是 12 个月时的总体体重减轻百分比 (TBWL%)。次要终点包括12个月随访后体重减轻≥5%、≥10%、≥15%和≥20%的患者比例，以及代谢、心血管和合并症的改善。

结果

我们在分析中纳入了 304 名患者（73% 为女性，93% 为白人，平均年龄 48.8 [12.4] 岁，BMI 40.9 [9.6] kg/m ^{2 ）。}12 个月时，患者的 TBWL 达到 13.4 (8.0)%（与基线相比， p  < 0.001）。使用较高剂量索马鲁肽治疗 12 个月时，无 T2DM 患者的 TBWL 为 16.9 (6.9)%，而无 T2DM 患者为 9.9 (8.4)%（与基线相比， p  < 0.001）。在该队列中，12 个月时，81% 的人达到 ≥5%，64% 的人达到 ≥10%，41% 的人达到 ≥15%，22% 的人达到 ≥20% TBWL。超重或肥胖患者的代谢、血脂、血压、肝功能测试和心血管疾病风险结果均显着改善。

结论

索马鲁肽在临床环境中显示出显着改善肥胖、代谢和心血管疾病风险结果。